BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15620390)

  • 1. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
    Amodio P; De Toni EN; Cavalletto L; Mapelli D; Bernardinello E; Del Piccolo F; Bergamelli C; Costanzo R; Bergamaschi F; Poma SZ; Chemello L; Gatta A; Perini G
    J Affect Disord; 2005 Jan; 84(1):93-8. PubMed ID: 15620390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
    Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
    Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C.
    Huckans M; Fuller B; Wheaton V; Jaehnert S; Ellis C; Kolessar M; Kriz D; Anderson JR; Berggren K; Olavarria H; Sasaki AW; Chang M; Flora KD; Loftis JM
    J Psychosom Res; 2015 Feb; 78(2):184-92. PubMed ID: 25219976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
    Raison CL; Woolwine BJ; Demetrashvili MF; Borisov AS; Weinreib R; Staab JP; Zajecka JM; Bruno CJ; Henderson MA; Reinus JF; Evans DL; Asnis GM; Miller AH
    Aliment Pharmacol Ther; 2007 May; 25(10):1163-74. PubMed ID: 17451562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved cognitive function as a consequence of hepatitis C virus treatment.
    Thein HH; Maruff P; Krahn MD; Kaldor JM; Koorey DJ; Brew BJ; Dore GJ
    HIV Med; 2007 Nov; 8(8):520-8. PubMed ID: 17944685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationship between emotional distress, cognitive performance and health - related quality of life in patients with hepatitis C prior to antiviral treatment].
    Rothenhäusler HB; Scherr M; Putz-Bankuti C; Kapper A; Stepan A; Baranyi A; Haas-Krammer A; Haas B; Stauber R
    Fortschr Neurol Psychiatr; 2009 Aug; 77(8):457-63. PubMed ID: 19676008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
    Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
    J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
    Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
    Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
    J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study.
    Fransen Van De Putte DE; Fischer K; Posthouwer D; Van Erpecum K; Mauser-Bunschoten EP
    Haemophilia; 2009 Mar; 15(2):544-51. PubMed ID: 19175422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C.
    Hilsabeck RC; Hassanein TI; Ziegler EA; Carlson MD; Perry W
    J Int Neuropsychol Soc; 2005 Jan; 11(1):16-22. PubMed ID: 15686604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.
    Schäfer M; Boetsch T; Laakmann G
    Addiction; 2000 Jul; 95(7):1101-4. PubMed ID: 10962774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
    Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
    Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.